Strategies to improve dendritic cell-based immunotherapy against cancer

Yonsei Medical Journal

Volumn 45, Issue SUPPL., 2004, Pages 48-52

  Song, Si Young ^a   Kim, Han Soo ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Dendritic cells; Flt 3 ligand; HSP; Immunotherapy; NK; Tumor lysates

Indexed keywords

FLT3 LIGAND; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; CANCER IMMUNOTHERAPY; CELL COUNT; CELL FUNCTION; CELL INTERACTION; CELL ISOLATION; CELL MATURATION; CELL TRANSPLANTATION; CELL TYPE; CELLULAR IMMUNITY; DENDRITIC CELL; DISEASE MODEL; EFFECTOR CELL; EX VIVO STUDY; FEASIBILITY STUDY; HEAT SHOCK; HUMAN; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; LYMPHOKINE ACTIVATED KILLER CELL; MONOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; PANCREAS CANCER; REVIEW; SAFETY; TUMOR CELL; TUMOR IMMUNITY;

EID: 3543019680     PISSN: 05135796     EISSN: None     Source Type: Journal    
DOI: 10.3349/ymj.2004.45.suppl.48     Document Type: Review

References (33)

1. Marincola FM, Jaffe EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: moelcular mechanisms and functional significance. Adv Immunol 2000;74:181-273.
2. Pawelec G. Tumor escape: antitumor effectors too much of a godd thing? Cancer Immunol Immunother 2004 In Press.
3. Fortis C, Foppoli M, Gianotti L, Galli L, Citterio G, Consgno G, et al. Increased interleukin-10 serum levels in patients with solid tumors. Cancer Lett 1996; 104:1-5.
4. Kiertscher SM, Luo J, Dubinett SM, Roth MD. Tumors promote altered maturation and early apoptosis of monocyte-derived dendritic cells. J Immunol 2000;164: 1269-76.
5. Wang H, Lee DA, Peng G, Guo Z, Li Y, Kiniwa Y, et al. Tumor-specific human CD4+ regulatory T cells and their ligands: implications for immunotherapy. Immunity 2004;20:107-18.
6. Steinman RM. The dendritic cell system and its role in immunogenicity. Ann Rev Immunol 1991;9:271-96.
7. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature 1998;392:245-52.
8. Parmiani G, Pilla L, Castelli C, Rivoltini L. Vaccination of patients with solid tumours. Ann Oncol 2003;14: 817-24.
9. Cranmer LD, Trevor KT, Hersh EM. Clinical applications of dendritic cell vaccination in the treatment of cancer. Cancer Immunol Immunother 2004 In Press.
10. Whiteside TL, Odoux C. Dendritic cell biology and cancer therapy. Cancer Immunol Immunother 2004 In Press.
11. Liyanage UK, Moore TT, Joo H-G, Tanaka Y, Herrmann V, Doherty G, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol 2002;169:2756-61.
12. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002;3:991-8.
13. Kobie JJ, Wu RS, Kurt RA, Lou S, Adelman MK, Whitesell LJ, et al. Transforming grwoth factor b inhibits the antigen-presenting functions and antitumor activity of dendritic cell vaccines. Cancer Res 2003;63: 1860-4.
14. Dong J, McPherson CM, Stambrook PJ. Flt-3 ligand. Cancer Biol Ther 2002;1:486-9.
15. Gabbianelli M, Pelosi E, Montesoro E, Valtieri M, Luchetti L, Somoggia P, et al. Multi-level effects of flt3 ligand on human hematopoiesis: expansion of putative stem cells and proliferation of granulomonocytic progenitors/monocytic precursors. Blood 1995;86:1661-70.
16. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JCL. Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med 1997,3:625-31.
17. Pulendran B, Banchereau J, Burkeholder S, Kraus E, Guinet E, Chalouni C, et al. Flt3-ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J Immunol 2000;165:566-72.
18. Rosnet O, Schiff C, Pebusque MJ, Marchetto S, Tonnelle C, Toiron Y, et al. Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells. Blood 1993;82:1110-9.
19. Thurner B, Haendle I, Roder C, Dieckmann D, Keikavoussi P, Jonuleit H, et al. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 1999;190:1669-78.
20. Banchereau J, Palucka AK, Dhodapkar M, Burkeholder S, Taquet N, Rolland A, et al. Immune and clinical responses in patients with metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res 2001;61:6451-8.
21. Liu B, DeFilippo AM, Li Z. Overcoming immune tolerance to cancer by heat shock protein vaccines. Mol Cancer Ther 2002;1:1147-51.
22. Todryk S, Melcher AA, Hardwick N, Linardakis E, Bateman A, Colombo MP, et al. Heat shock protein 70 induced during tumor cell killing induces Th1 cytokines and targets immature dendritic cell precursors to enhance antigen uptake. J Immunol 1999;163:1398-408.
23. Lipsker D, Ziylan U, Spehner D, Proamer F, Bausinger H, Jeannin P, et al. Heat shock proteins 70 and 60 share common receptors which are expressed on human moncyte-derived but not epidermanl dendritic cells. Eur J Immunol 2002;32:322-32.
24. Berwin B, Hart JP, Pizzo SV, Nicchitta CV. CD91-independent cross-presentation of GRP94(gp96)-associated peptides. J Immunol 2002;168:4282-6.
25. Schnurr M, Galambos P, Scholtz C, Then F, Dauer M, Endres S, et al. Tumor cell lysate-pulsed human dendritic cells induce a T-cell response against pancreatic carcinoma cells: an in vitro model for the assessmet of tumor vaccines. Cancer Res 2001;61:6445-50.
26. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LDJ. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J Exp Med 1996;183:283-7.
27. Fields RCk, Shimizu K, Mule JJ. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci U S A 1998;95:9482-7.
28. Kugler A, Stuhler G, Walden P, Zoller G, Zobywalski A, Brossart P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000;6:332-6.
29. Ettinghausen SE, Rosenberg SA. Immunotherapy and gene therapy of cancer. Adv Surg 1995;28:223-54.
30. Takahashi H, Nakada T, Puisieux I. Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice. Science 1993;259:1460-3.
31. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu Y-J, et al. Immunobiology of dendritic cells. Ann Rev Immunol 2000;18:767-811.
32. Valteau-Cousnet D, Leboulaire C, Maincent K, Tournier M, Hartmann O, Benard J, et al. Dendritic cells for NK/LAK activation: rationale for multicellular immunotherpay in neuroblastoma patients. Blood 2002;100: 2554-61.
33. Fernandez NC, Lozier A, Flament C, Ricciardi-Castagnoli P, Bellet D, Suter M, et al. Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 1999;5:405-11.